{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:44:56Z","timestamp":1782603896227,"version":"3.54.5"},"reference-count":75,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2021,12,1]]},"DOI":"10.1001\/jamacardio.2021.3444","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T15:36:24Z","timestamp":1628609784000},"page":"1451","source":"Crossref","is-referenced-by-count":104,"title":["Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine\u2013Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis"],"prefix":"10.1001","volume":"6","author":[{"given":"John G.","family":"Rizk","sequence":"first","affiliation":[{"name":"Arizona State University, Edson College, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashish","family":"Gupta","sequence":"additional","affiliation":[{"name":"John Ochsner Heart and Vascular Institute, Ochsner Clinical School\u2014The University of Queensland School of Medicine, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha","family":"Sardar","sequence":"additional","affiliation":[{"name":"John Ochsner Heart and Vascular Institute, Ochsner Clinical School\u2014The University of Queensland School of Medicine, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon Michael","family":"Henry","sequence":"additional","affiliation":[{"name":"The Heart Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Lewin","sequence":"additional","affiliation":[{"name":"National Coalition on Health Care, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[{"name":"Section of Clinical Biochemistry, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[{"name":"John Ochsner Heart and Vascular Institute, Ochsner Clinical School\u2014The University of Queensland School of Medicine, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"hrv210003r1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.drudis.2020.11.025","article-title":"Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.","volume":"26","author":"Rizk","year":"2021","journal-title":"Drug Discov Today"},{"issue":"4","key":"hrv210003r2","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1161\/STR.0b013e31820a8364","article-title":"Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"42","author":"Saposnik","year":"2011","journal-title":"Stroke"},{"issue":"10","key":"hrv210003r3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11910-019-0988-x","article-title":"Cerebral venous thrombosis: an update.","volume":"19","author":"Ferro","year":"2019","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"9","key":"hrv210003r4","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nrneurol.2017.104","article-title":"Cerebral venous thrombosis.","volume":"13","author":"Silvis","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"hrv210003r5","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1161\/STROKEAHA.121.035564","article-title":"Diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia.","volume":"52","author":"Furie","year":"2021","journal-title":"Stroke"},{"issue":"4","key":"hrv210003r6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1159\/000509802","article-title":"Cerebral venous thrombosis: a comprehensive review.","volume":"83","author":"Idiculla","year":"2020","journal-title":"Eur Neurol"},{"issue":"Pt 3","key":"hrv210003r7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/brain\/awh412","article-title":"Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome.","volume":"128","author":"S\u00e9bire","year":"2005","journal-title":"Brain"},{"issue":"4","key":"hrv210003r9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1177\/1747493020959216","article-title":"Cerebrovascular events and outcomes in hospitalized patients with COVID-19: the SVIN COVID-19 Multinational Registry.","volume":"16","author":"Siegler","year":"2021","journal-title":"Int J Stroke"},{"issue":"22","key":"hrv210003r10","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"hrv210003r11","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"hrv210003r12","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-03744-4","article-title":"Antibody epitopes in vaccine-induced immune thrombotic thrombocytopenia.","author":"Huynh","year":"2021","journal-title":"Nature"},{"issue":"24","key":"hrv210003r13","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1001\/jama.2021.7517","article-title":"US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.","volume":"325","author":"See","year":"2021","journal-title":"JAMA"},{"key":"hrv210003r14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ajem.2021.05.054","article-title":"Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines.","volume":"49","author":"Long","year":"2021","journal-title":"Am J Emerg Med"},{"issue":"4","key":"hrv210003r15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jacc.2021.06.001","article-title":"Cerebral venous sinus thrombosis in the US population, after adenovirus-based SARS-CoV-2 vaccination, and after COVID-19.","volume":"78","author":"Bikdeli","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hrv210003r16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41541-021-00315-6","article-title":"ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets.","volume":"6","author":"Marsh","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"15","key":"hrv210003r17","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1001\/jama.2021.2927","article-title":"The Johnson & Johnson Vaccine for COVID-19.","volume":"325","author":"Livingston","year":"2021","journal-title":"JAMA"},{"issue":"13","key":"hrv210003r20","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1161\/CIRCULATIONAHA.111.067835","article-title":"Cerebral venous thrombosis.","volume":"125","author":"Piazza","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"hrv210003r21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1053\/j.seminhematol.2007.02.004","article-title":"Epidemiology and risk factors for venous thrombosis.","volume":"44","author":"Cushman","year":"2007","journal-title":"Semin Hematol"},{"issue":"3","key":"hrv210003r22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000083248","article-title":"Delay in hospital admission of patients with cerebral vein and dural sinus thrombosis.","volume":"19","author":"Ferro","year":"2005","journal-title":"Cerebrovasc Dis"},{"issue":"4","key":"hrv210003r23","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1182\/blood-2005-12-4795","article-title":"Natural history of cerebral vein thrombosis: a systematic review.","volume":"108","author":"Dentali","year":"2006","journal-title":"Blood"},{"issue":"9","key":"hrv210003r24","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1161\/STROKEAHA.110.581223","article-title":"Venous thromboembolic events after cerebral vein thrombosis.","volume":"41","author":"Miranda","year":"2010","journal-title":"Stroke"},{"issue":"2","key":"hrv210003r25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/1358863X19898253","article-title":"Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management.","volume":"25","author":"Hogan","year":"2020","journal-title":"Vasc Med"},{"issue":"7","key":"hrv210003r26","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1046\/j.1538-7836.2003.00270.x","article-title":"Heparin-induced thrombocytopenia.","volume":"1","author":"Chong","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"1","key":"hrv210003r28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1056\/NEJMra2106545","article-title":"Cerebral venous thrombosis.","volume":"385","author":"Ropper","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"hrv210003r29","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination.","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"key":"hrv210003r30","doi-asserted-by":"crossref","DOI":"10.1016\/j.pcad.2021.05.001","article-title":"Covid-19 vaccine- induced thrombosis and thrombocytopenia-a commentary on an important and practical clinical dilemma.","author":"Gupta","year":"2021","journal-title":"Prog Cardiovasc Dis"},{"issue":"7","key":"hrv210003r31","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","article-title":"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.","volume":"27","author":"Simpson","year":"2021","journal-title":"Nat Med"},{"issue":"23","key":"hrv210003r32","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1056\/NEJMe2106315","article-title":"SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia.","volume":"384","author":"Cines","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"hrv210003r35","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1161\/STROKEAHA.108.543884","article-title":"Cerebral venous and sinus thrombosis in women.","volume":"40","author":"Coutinho","year":"2009","journal-title":"Stroke"},{"issue":"8767","key":"hrv210003r36","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/0140-6736(91)90607-Q","article-title":"Heparin treatment in sinus venous thrombosis.","volume":"338","author":"Einh\u00e4upl","year":"1991","journal-title":"Lancet"},{"issue":"3","key":"hrv210003r37","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1161\/01.STR.30.3.484","article-title":"Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis.","volume":"30","author":"de Bruijn","year":"1999","journal-title":"Stroke"},{"issue":"9","key":"hrv210003r38","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood-2017-04-778993","article-title":"Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review.","volume":"130","author":"Warkentin","year":"2017","journal-title":"Blood"},{"issue":"1","key":"hrv210003r39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11239-006-5571-z","article-title":"New concepts in heparin-induced thrombocytopenia: diagnosis and management.","volume":"21","author":"Spinler","year":"2006","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"hrv210003r40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5492\/wjccm.v8.i6.87","article-title":"Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation.","volume":"8","author":"Burstein","year":"2019","journal-title":"World J Crit Care Med"},{"issue":"3","key":"hrv210003r41","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.pcad.2020.02.002","article-title":"Anticoagulation management strategies in heart transplantation.","volume":"63","author":"Rizk","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"issue":"5","key":"hrv210003r42","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1136\/practneurol-2019-002415","article-title":"Cerebral venous thrombosis: a practical guide.","volume":"20","author":"Ulivi","year":"2020","journal-title":"Pract Neurol"},{"issue":"1","key":"hrv210003r43","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/archinte.164.1.66","article-title":"Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia.","volume":"164","author":"Srinivasan","year":"2004","journal-title":"Arch Intern Med"},{"issue":"5","key":"hrv210003r44","first-page":"1055","article-title":"Safety of thrombolysis in cerebral venous thrombosis. a systematic review of the literature.","volume":"104","author":"Dentali","year":"2010","journal-title":"Thromb Haemost"},{"issue":"3","key":"hrv210003r45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000068833","article-title":"Thrombolytics for cerebral sinus thrombosis: a systematic review.","volume":"15","author":"Canh\u00e3o","year":"2003","journal-title":"Cerebrovasc Dis"},{"issue":"13","key":"hrv210003r46","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s40265-020-01367-z","article-title":"Pharmaco-immunomodulatory therapy in COVID-19.","volume":"80","author":"Rizk","year":"2020","journal-title":"Drugs"},{"issue":"8","key":"hrv210003r47","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/17474086.2019.1636645","article-title":"High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review.","volume":"12","author":"Warkentin","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"hrv210003r48","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.transci.2018.06.007","article-title":"Intravenous immunoglobulin as an adjunct therapy in persisting heparin-induced thrombocytopenia.","volume":"57","author":"Park","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"hrv210003r49","first-page":"1","article-title":"Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty.","author":"Hwang","year":"2020","journal-title":"Platelets"},{"key":"hrv210003r50","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2107051","article-title":"Adjunct immune globulin for vaccine-induced thrombotic thrombocytopenia.","author":"Bourguignon","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"hrv210003r56","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/a-1469-7481","article-title":"Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH.","volume":"41","author":"Oldenburg","year":"2021","journal-title":"Hamostaseologie"},{"issue":"3","key":"hrv210003r57","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.chest.2017.03.050","article-title":"IVIg for treatment of severe refractory heparin-induced thrombocytopenia.","volume":"152","author":"Padmanabhan","year":"2017","journal-title":"Chest"},{"issue":"8500","key":"hrv210003r58","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(86)92511-0","article-title":"Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients.","volume":"2","author":"Woodruff","year":"1986","journal-title":"Lancet"},{"issue":"1","key":"hrv210003r59","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/rth2.2017.1.issue-1","article-title":"Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG).","volume":"1","author":"Doucette","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"hrv210003r60","article-title":"Refractory heparin-induced thrombocytopenia with cerebral venous sinus thrombosis treated with IVIg, steroids, and a combination of anticoagulants: a case report.","volume":"7","author":"Gonzales","year":"2019","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"8","key":"hrv210003r61","doi-asserted-by":"publisher","first-page":"E301","DOI":"10.1002\/ajh.v96.8","article-title":"Successful treatment of thrombotic thrombocytopenia with cerebral sinus venous thrombosis following Ad26.COV2.S vaccination.","volume":"96","author":"George","year":"2021","journal-title":"Am J Hematol"},{"issue":"9","key":"hrv210003r62","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1182\/blood-2014-10-605493","article-title":"Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality.","volume":"125","author":"Goel","year":"2015","journal-title":"Blood"},{"issue":"11","key":"hrv210003r63","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1111\/jth.2017.15.issue-11","article-title":"Autoimmune heparin-induced thrombocytopenia.","volume":"15","author":"Greinacher","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"7","key":"hrv210003r64","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0735-1097(98)00134-X","article-title":"Heparin-induced thrombocytopenia.","volume":"31","author":"Brieger","year":"1998","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"hrv210003r65","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1182\/blood.V91.2.549","article-title":"Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation\/aggregation induced by sera from heparin-induced thrombocytopenia patients.","volume":"91","author":"Polg\u00e1r","year":"1998","journal-title":"Blood"},{"key":"hrv210003r67","first-page":"1","article-title":"Low-dose aspirin for early COVID-19: does the early bird catch the worm?","volume":"1-4","author":"Rizk","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"hrv210003r68","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1213\/ANE.0b013e3181c3c1cd","article-title":"Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia.","volume":"110","author":"Welsby","year":"2010","journal-title":"Anesth Analg"},{"key":"hrv210003r69","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2109465","article-title":"Therapeutic plasma exchange in vaccine-induced immune thrombotic thrombocytopenia.","author":"Patriquin","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"hrv210003r70","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.","volume":"48","author":"Cambridge","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"2","key":"hrv210003r71","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.transci.2013.01.007","article-title":"Refractory heparin induced thrombocytopenia with thrombosis (HITT) treated with therapeutic plasma exchange and rituximab as adjuvant therapy.","volume":"49","author":"Schell","year":"2013","journal-title":"Transfus Apher Sci"},{"issue":"11","key":"hrv210003r72","doi-asserted-by":"crossref","DOI":"10.1172\/JCI151092","article-title":"Is complement the culprit behind COVID-19 vaccine-related adverse reactions?","volume":"131","author":"Mastellos","year":"2021","journal-title":"J Clin Invest"},{"issue":"9","key":"hrv210003r73","first-page":"735","article-title":"Complement: activation, consequences, and control.","volume":"48","author":"James","year":"1982","journal-title":"Am J Med Technol"},{"issue":"4","key":"hrv210003r74","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.tmrv.2019.09.004","article-title":"Eculizumab and beyond: the past, present, and future of complement therapeutics.","volume":"33","author":"Patriquin","year":"2019","journal-title":"Transfus Med Rev"},{"key":"hrv210003r8","doi-asserted-by":"crossref","unstructured":"Taquet? M, Husain? M, Geddes? JR, Luciano? S, Harrison? PJ. Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537, 913 COVID-19 cases.? medRxiv? 2021.04.27.21256153. doi:10.1101\/2021.04.27.21256153","DOI":"10.1101\/2021.04.27.21256153"},{"key":"hrv210003r18","unstructured":"Shimabukuro? T; CDC COVID-19 Vaccine Task Force Vaccine Safety Team. Reports of cerebral venous sinus thrombosis with thrombocytopenia after Janssen COVID-19 vaccine. National Center for Immunization & Respiratory Diseases. Accessed June 28, 2021. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-04-23\/03-COVID-Shimabukuro-508.pdf"},{"key":"hrv210003r19","doi-asserted-by":"crossref","unstructured":"Sangli? S, Virani? A, Cheronis? N, . Thrombosis with thrombocytopenia after the messenger RNA-1273 vaccine. Ann Intern Med. 2021;L21-L0244. doi:10.7326\/L21-024434181446","DOI":"10.7326\/L21-0244"},{"key":"hrv210003r27","unstructured":"Centers for Disease Control and Prevention. Advisory Committee on Immunization Practice (ACIP) ACIP Presentation Slides. Accessed June 14, 2021. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/slides-2021-04-23.html."},{"key":"hrv210003r33","doi-asserted-by":"crossref","unstructured":"Vayne? C, Rollin? J, Gruel? Y, . PF4 Immunoassays in vaccine-induced thrombotic thrombocytopenia. N Engl J Med. 2021;c2106383. doi:10.1056\/NEJMc210638334010527","DOI":"10.1056\/NEJMc2106383"},{"key":"hrv210003r34","doi-asserted-by":"crossref","unstructured":"Favaloro? EJ. Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia. Int J Lab Hematol. Published online June 17, 2021. doi:10.1111\/ijlh.1362934138513","DOI":"10.1111\/ijlh.13629"},{"key":"hrv210003r51","unstructured":"American Society of Hematology. Thrombosis with thrombocytopenia syndrome (also termed vaccine-induced thrombotic thrombocytopenia). Accessed June 17, 2021. https:\/\/www.hematology.org\/covid-19\/vaccine-induced-immune-thrombotic-thrombocytopenia"},{"key":"hrv210003r52","unstructured":"International Society on Thrombosis and Haemostasis. Interim guidance for the diagnosis and treatment on vaccine-induced immune thrombotic thrombocytopenia. Accessed June 17, 2021. https:\/\/cdn.ymaws.com\/www.isth.org\/resource\/resmgr\/ISTH_VITT_Guidance_2.pdf"},{"key":"hrv210003r53","unstructured":"Pavord? J, Lester? W, Makris? M, Scully? M, Hunt? B. Guidance from the Expert Haematology Panel (EHP) on COVID-19 vaccine-induced immune thrombocytopenia and thrombosis (VITT). Accessed June 17, 2021. https:\/\/b-s-h.org.uk\/media\/19718\/guidance-v20-20210528-002.pdf"},{"key":"hrv210003r54","unstructured":"Thrombosis and Haemostasis Society of Australia and New Zealand. Suspected vaccine induced immune thrombotic thrombocytopenia (VITT). Accessed June 17, 2021. https:\/\/www.thanz.org.au\/documents\/item\/591"},{"key":"hrv210003r55","unstructured":"Table? S. COVID-19 Advisory for Ontario. Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following Adenovirus Vector COVID-19 Vaccination. Accessed June 17, 2021. https:\/\/covid19-sciencetable.ca\/sciencebrief\/vaccine-induced-immune-thrombotic-thrombocytopenia-vitt-following-adenovirus-vector-covid-19-vaccination\/"},{"key":"hrv210003r66","unstructured":"Public Health England. Information for healthcare professionals on blood clotting following COVID-19 vaccination. Accessed June 16, 2021. https:\/\/www.gov.uk\/government\/publications\/covid-19-vaccination-blood-clotting-information-for-healthcare-professionals\/information-for-healthcare-professionals-on-blood-clotting-following-covid-19-vaccination."},{"key":"hrv210003r75","doi-asserted-by":"crossref","unstructured":"Tiede? A, Sachs? UJ, Czwalinna? A, . Prothrombotic immune thrombocytopenia after COVID-19 vaccine. Blood. Published online April 28, 2021. doi:10.1182\/blood.202101195833909050","DOI":"10.1182\/blood.2021011958"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2783051\/jamacardiology_rizk_2021_rv_210003_1637772506.3757.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T16:03:20Z","timestamp":1639411400000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2783051"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2021.3444","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,1]]}}}